Robert Featherstone, PhD

Assistant Professor of Research Psychiatry and the Behavioral Sciences

Image of Robert Featherstone, PhD
Is this your profile? Click to edit

Overview

Robert E. Featherstone, Ph.D., is an Assistant Professor of Research in the Department of Psychiatry and Behavioral Sciences at the University of Southern California. His research focuses on the neurobiology, cognitive dysfunction, and treatment of schizophrenia and depression, integrating both preclinical animal models and human clinical research.

Dr. Featherstone’s work examines the neural mechanisms underlying cognitive impairments associated with psychiatric illness and seeks to identify novel therapeutic strategies to improve cognitive and functional outcomes. His research combines behavioral neuroscience, neuropsychopharmacology, and electrophysiology, with particular expertise in EEG and event-related potential (ERP) biomarkers for psychiatric drug discovery and translational neuroscience.

Current projects investigate glutamatergic signaling pathways, NMDA receptor function, and synaptic mechanisms that contribute to cognitive deficits in neuropsychiatric disorders. By integrating behavioral, molecular, and electrophysiological approaches across animal and human studies, his research aims to advance the development of mechanism-based treatments that improve both symptoms and cognitive functioning in individuals with serious mental illness.

Publications

  • Parvalbumin Cell Ablation of NMDA-R1 Leads to Altered Phase, But Not Amplitude, of Gamma-Band Cross-Frequency Coupling. Brain Connect. 2019 04; 9(3):263-272.. View in PubMed
  • Src deficient mice demonstrate behavioral and electrophysiological alterations relevant to psychiatric and developmental disease. Prog Neuropsychopharmacol Biol Psychiatry. 2019 07 13; 93:84-92.. View in PubMed
  • Pyramidal cell-selective GluN1 knockout causes impairments in salience attribution and related EEG activity. Exp Brain Res. 2018 03; 236(3):837-846.. View in PubMed
  • Mismatch negativity in preclinical models of schizophrenia. Schizophr Res. 2018 01; 191:35-42.. View in PubMed
  • Amygdala activity associated with social choice in mice. Behav Brain Res. 2017 08 14; 332:84-89.. View in PubMed
  • GABA-B Agonist Baclofen Normalizes Auditory-Evoked Neural Oscillations and Behavioral Deficits in the Fmr1 Knockout Mouse Model of Fragile X Syndrome. eNeuro. 2017 Jan-Feb; 4(1).. View in PubMed
  • The mGluR2 positive allosteric modulator, SAR218645, improves memory and attention deficits in translational models of cognitive symptoms associated with schizophrenia. Sci Rep. 2016 10 13; 6:35320.. View in PubMed
  • Multiple Drug Treatments That Increase cAMP Signaling Restore Long-Term Memory and Aberrant Signaling in Fragile X Syndrome Models. Front Behav Neurosci. 2016; 10:136.. View in PubMed
  • Mouse Model of Chromosome 15q13.3 Microdeletion Syndrome Demonstrates Features Related to Autism Spectrum Disorder. J Neurosci. 2015 Dec 09; 35(49):16282-94.. View in PubMed
  • Ceftriaxone reverses ketamine-induced lasting EEG and astrocyte alterations in juvenile mice. Drug Alcohol Depend. 2015 Nov 01; 156:14-20.. View in PubMed